Abstract:Background & Aims Accumulating evidence has indicated the presence of mature miRNAs in the nucleus, but their effects on steatohepatitis remain elusive. We have previously demonstrated that the intranuclear miR-204-3p in macrophages protects against atherosclerosis, which shares multiple risk factors with metabolic dysfunction-associated steatotic liver disease (MASLD). Herein, we aimed to explore the functional significance of miR-204-3p in steatohepatitis. Methods miR-204-3p levels and subcellular localization were assessed in the livers and peripheral blood mononuclear cells (PBMCs) of MASLD patients. Wild-type mice fed a high-fat diet (HFD) or methionine- and choline-deficient (MCD) diet were administered an adeno-associated virus system containing miR-204-3p to determine the effect of miR-204-3p on steatohepatitis. Co-culture systems were applied to investigate the crosstalk between macrophages and hepatocytes or hepatic stellate cells (HSCs). Multiple high-throughput epigenomic sequencings were performed to explore miR-204-3p targets. Results miR-204-3p expression decreased in the livers and macrophages in mice and patients with fatty liver. In MASLD patients, miR-204-3p levels in PBMCs were inversely related to the severity of hepatic inflammation and damage. Macrophage-specific miR-204-3p overexpression reduced steatohepatitis in HFD- or MCD diet-fed mice. miR-204-3p-overexpressing macrophages inhibited TLR4/JNK signaling and pro-inflammatory cytokine release, thereby limiting fat deposition and inflammation in hepatocytes and fibrogenic activation in HSCs. Epigenomic profiling identified miR-204-3p as a specific regulator of ULK1 expression. ULK1 transcription and VPS34 complex activation by intranuclear miR-204-3p improved autophagic flux, promoting the anti-inflammatory effects of miR-204-3p in macrophages. Conclusions miR-204-3p inhibits macrophage inflammation, coordinating macrophage actions on hepatocytes and HSCs to ameliorate steatohepatitis. Macrophage miR-204-3p may be a therapeutic target for MASLD. Impact and implications Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic inflammatory disease ranging from simple steatosis to non-alcoholic steatohepatitis. However, the molecular mechanisms underlying the progression of MASLD remain incompletely understood. Here, we demonstrate that miR-204-3p levels in circulating peripheral blood mononuclear cells are negatively correlates with disease severity in patients with MASLD. Nuclear miR-204-3p activates ULK1 transcription and improves autophagic flux, limiting macrophage activation and hepatic steatosis. Our study provides a novel understanding of the mechanism of macrophage autophagy and inflammation in steatohepatitis and suggests that miR-204-3p may act as a potential therapeutic target for MASLD.

MicroRNA-206-3p suppresses hepatic lipogenesis and cholesterol synthesis while driving cholesterol efflux

MicroRNA-206 As a Potential Cholesterol-lowering Drug is Superior to Statins in Mice

Activation of microRNA-378a-3p biogenesis promotes hepatic secretion of VLDL and hyperlipidemia by modulating ApoB100-Sortilin1 axis.

MicroRNA-185 modulates CYP7A1 mediated cholesterol-bile acid metabolism through post-transcriptional and post-translational regulation of FoxO1

MicroRNA-376b-3p ameliorates nonalcoholic fatty liver disease by targeting FGFR1 and regulating lipid oxidation in hepatocytes

Hepatic miR-378 modulates serum cholesterol levels by regulating hepatic bile acid synthesis

Effect of Mirna-10b in Regulating Cellular Steatosis Level by Targeting Ppar-Alpha Expression, A Novel Mechanism for the Pathogenesis of Nafld

Effect Of Mir-34a In Regulating Steatosis By Targeting Ppar Alpha Expression In Nonalcoholic Fatty Liver Disease

Mir-149 Controls Non-Alcoholic Fatty Liver by Targeting Fgf-21

Mir-212-5p Suppresses Lipid Accumulation by Targeting FAS and SCD1.

MicroRNAs 185, 96, and 223 Repress Selective High-Density Lipoprotein Cholesterol Uptake Through Posttranscriptional Inhibition

MicroRNA-182 Promotes Lipoprotein Lipase Expression and Atherogenesisby Targeting Histone Deacetylase 9 in Apolipoprotein E-Knockout Mice.

miR-552-3p modulates transcriptional activities of FXR and LXR to ameliorate hepatic glycolipid metabolism disorder

MicroRNA-467b Targets LPL Gene in RAW 264.7 Macrophages and Attenuates Lipid Accumulation and Proinflammatory Cytokine Secretion

MicroRNA-590 Attenuates Lipid Accumulation and Pro-Inflammatory Cytokine Secretion by Targeting Lipoprotein Lipase Gene in Human THP-1 Macrophages.

MiR-29 Regulates de novo Lipogenesis in the Liver and Circulating Triglyceride Levels in a Sirt1-Dependent Manner

Reduced Mir-200B and Mir-200C Expression Contributes to Abnormal Hepatic Lipid Accumulation by Stimulating JUN Expression and Activating the Transcription of Srebp1.

MicroRNA-122 Inhibits Lipid Droplet Formation and Hepatic Triglyceride Accumulation via Yin Yang 1

Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice

Inhibiting miRNA-146a suppresses mouse gallstone formation by regulating LXR/megalin/cubilin-media cholesterol absorption

Liver MicroRNA-291b-3p Promotes Hepatic Lipogenesis Through Negative Regulation of Adenosine 5′-Monophosphate (Amp)-Activated Protein Kinase Α1